Current concepts on apoptotic signalling pathways: New targets for anticancer strategies;Actualités sur les voies de signalisation de l'apoptose: Nouvelles cibles de la chimiothérapie

Bulletin du Cancer

Volumn 90, Issue 1, 2003, Pages 9-17

  Ségal Bendirdjian, Evelyne ^a   Hillion, Josette ^a   Ahmed Belmokhtar, Chafké ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Apoptosis; Bcl2; Chemotherapy; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT;

APOPTOSIS; CARCINOGENESIS; HOMEOSTASIS; MOLECULAR BIOLOGY; PHYSIOLOGY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CASPASES; ENZYME ACTIVATION; LIGANDS; MEMBRANE GLYCOPROTEINS; MITOCHONDRIA; NEOPLASMS; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037283063     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Mehlen P, Bredesen DE. Dependence receptors: links between apoptosis, nervous system development and control of tumorigenesis. Bull Cancer 2000; 87: 537-41.
2. Bettaieb A, Sordet O, Belon JP, Solary E. Apoptosis and chemotherapy Bull Cancer 1999; 86: 41-6.
3. Solary E, Micheau O, Dimanche-Boitrel MT, Martin F. The Fas/Fas-ligand system: implications in the antitumor immune response and in the activity of cytotoxic agents. Bull Cancer 1998; 85: 685-94.
4. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem 2000; 69: 217-45.
5. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000; 102: 1-4.
6. Bratton SB, Cohen GM. Apoptotic death sensor: an organelle's alter ego? Trends Pharmacol Sci 2001; 22: 306-15.
7. Schmitz I, Kirchhoff S, Krammer PH. Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol 2000; 32: 1123-36.
8. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-21.
9. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-8.
10. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med 1999; 5: 157-63.
11. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833-40.
12. Harper N, Farrow SN, Kaptein A, Cohen GM, MacFarlane M. Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases. J Biol Chem 2001; 276: 34743-52.
13. Goyal L. Cell death inhibition: keeping caspases in check. Cell 2001; 104: 805-8.
14. Martinou JC, Green DR. Breaking the mitochondrial barrier. Rev Mol Cell Biol 2001; 2: 63-7.
15. Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002; 9: 505-12.
16. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediatot of p53-induced apoptosis. Science 2000; 288: 1053-8.
17. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7: 673-82.
18. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683-94.
19. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasset A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 1999; 3: 287-96.
20. Puthalakath H, Villunger A, O'Reilly LA, Beaumont JG, Coultas L, Cheney RE, et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 2001; 293: 1829-32.
21. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001; 15: 1481-6.
22. Theodorakis P, Lomonosova E, Chinnadurai G. Critical requirement of BAX for manifestation of apoptosis induced by multiple stimuli in human epithelial cancer cells. Cancer Res 2002; 62: 3373-6.
23. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nature Med 2002; 8: 274-81.
24. Cain K, Bratton SB, Langlais C, Walker G, Btown DG, Sun XM, et al. Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes. J Biol Chem 2000; 275: 6067-70.
25. Acehan D, Jiang X, Morgan DG, Heuser JE, Wang X, Akey CW. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell 2002; 9: 423-32.
26. Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999; 284: 156-9.
27. Jia L, Srinivasula SM, Liu FT, Newland AC, Fernandes-Alnemri T, Alnemri ES, et al. Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood 2001; 98: 414-21.
28. Wolf BB, Schuler M, Li W, Eggers-Sedlet B, Lee W, Tailor P, et al. Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J Biol Chem 2001; 276: 34244-51.
29. Liu JR, Opipari AW, Tan L, Jiang Y, Zhang Y, Tang H, et al. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 2002; 62: 924-31.
30. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207-11.
31. Benedict MA, Hu Y, Inohara N, Nunez G. Expression and functional analysis of Apaf-1 isoforms. Extra Wd-40 repeat is required for cytochrome c binding and regulated activation of procaspase-9. J Biol Chem 2000; 275: 8461-8.
32. Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002; 297: 1352-4.
33. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 2002; 16: 33-45.
34. Borner C, Monney L. Apoptosis without caspases: an inefficient molecular guillotine? Cell Death Differ 1999; 6: 497-507.
35. Arnoult D, Tatischeff I, Estaquier J, Girard M, Sureau F, Tissier JP, et al. On the evolutionary conservation of the cell death pathway: mitochondtial release of an apoptosis-inducing factor during Dictyostelium discoideum cell death. Mol Biol Cell 2001; 12: 3016-30.
36. Belmokhtar CA, Hillion J, Segal-Bendirdjian E. Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms. Oncogene 2001; 20: 3354-62.
37. Rao RV, Castro-Obregon S, Frankowski H, Schuler M, Stoka V, del Rio G, et al. Coupling endoplasmic reticulum stress to the cell death program: An Apaf-1-independent intrinsic pathway. J Biol Chem 2002; 277: 21836-42.
38. Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, et al. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nature Cell Biol 2001; 3: 128-33.
39. Zheng L, Schickling O, Peter ME, Lenardo MJ. The death effector domain-associated factor plays distinct regulatory roles in the nucleus and cytoplasm. J Biol Chem 2001; 276: 31945-52.
40. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR. et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nature Med 2000; 6: 564-7.
41. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U, et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000; 356: 827-8.
42. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxiciry. Nature Med 2001; 7: 954-60.
43. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001; 61: 1645-51.
44. Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 2002; 38: 167-76.
45. Wu XX, Kakehi Y, Mizutani Y, Kamoto T, Kinoshita H, Isogawa Y, et al. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int J Oncol 2002; 20: 949-54.
46. Vignati S, Codegoni A, Polato F, Broggini M. Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur J Cancer 2002; 38: 177-83.
47. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002; 277: 22320-9.
48. Ohtsuka T, Zhou T. Bisindolylmaleimide VIII enhances DR5-mediated apoptosis through the MKK4/JNK/p38 kinase and the mitochondrial pathways. J Biol Chem 2002; 277: 29294-303.
49. Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 2002; 99: 326-35.
50. Stadheim TA, Suh N, Ganju N, Sporn MB, Eastman A. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells. J Biol Chem 2002; 277: 16448-55.
51. Ito Y, Pandey P, Sporn MB, Datta R, Kharbanda S, Kufe D. The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. Mol Pharmacol 2001; 59: 1094-9.
52. Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, et al. Identificarion of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nature Cell Biol 2001; 3: 173-82.
53. Kim KM, Giedt CD, Basanez G, O'Neill JW, Hill JJ, Han YH, et al. Biophysical characterization of recombinant human Bcl-2 and its interactions with an inhibitory ligand, antimycin A. Biochemistry 2001; 40: 4911-22.
54. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J, et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nature Cell Biol 2001; 3: 183-91.
55. Chin JW, Grotzfeld RM, Fabian MA, Schepartz A. Methodology for optimizing functional miniature proteins based on avian pancreatic polypeptide using phage display. Bioorg Med Chem Lett 2001; 11: 1501-5.
56. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nature Med 1999; 5: 1032-8.
57. Belzacq AS, Jacotot E, Vieira HL, Mistro D, Granville DJ, Xie Z, et al. Apoptosis induction by the photosensitizer verteporfin: identification of mitochondrial adenine nucleotide translocator as a critical target. Cancer Res 2001; 61: 1260-4.